Enanta's Zelicapavir Shows Positive Phase 2b Results for RSV in High-Risk Adults
Enanta Pharmaceuticals Inc. (NASDAQ:ENTA) is one of the best hot stocks to invest in.
Enanta Pharmaceuticals Inc (ENTA)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Farallon Capital Thomas Steyer | 2,418,202 | $35,257,385 | -16% | 0.16% |
| 2. | Deep Track Capital David Kroin | 1,444,167 | $21,055,955 | -27% | 0.31% |
| 3. | ADAR1 Capital Management Daniel Schneeberger | 1,344,510 | $19,602,956 | +2518% | 0.9% |
| 4. | Spruce Street Capital Alex Rosen And Simon Basseyn | 1,088,731 | $15,873,698 | +17% | 3.11% |
| 5. | Millennium Management Israel Englander | 643,967 | $9,389,039 | -27% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $5.69 | 45,000 | $256,050.00 | 846,638 | 2025-02-12 | Filing | |
| $24.45 | 500 | $12,222.50 | 1,900 | 2016-05-11 | Filing | |
| $27.04 | 2,000 | $54,080.00 | 15,295 | 2016-02-12 | Filing | |
| $34.20 | 600 | $20,520.00 | 2,000 | 2015-02-19 | Filing | |
| $33.69 | 400 | $13,476.00 | 1,400 | 2015-02-18 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $14.23 | 323 | $4,596.29 | 8,377 | 2025-12-05 | Filing | |
| $14.23 | 542 | $7,712.66 | 16,348 | 2025-12-05 | Filing | |
| $14.23 | 798 | $11,355.54 | 21,792 | 2025-12-05 | Filing | |
| $14.23 | 1,394 | $19,836.62 | 38,329 | 2025-12-05 | Filing | |
| $14.23 | 2,106 | $29,968.38 | 30,620 | 2025-12-05 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 3,654,920 | $53,252,184 | 0.02% | |
| 2. | 3,244,448 | $47,304,051 | 0% | |
| 3. | 1,211,769 | $17,667,592 | 0% | |
| 4. | 1,011,494 | $14,747,583 | 0% | |
| 5. | 776,634 | $11,325,842 | 0% |
News See All
12 Best Hot Stocks to Invest In
On September 24, Ryan Detrick, Carson Group chief market strategist, joined CNBC's 'Power Lunch' to discuss why he still expects a strong end-of-year rally.
11 Best Breakout Stocks to Buy According to Analysts
In this article, we discuss 11 Best Breakout Stocks to Buy According to Analysts.
7 Best Nano Cap Stocks To Invest In
In this article, we will look at the 7 Best Nano Cap Stocks To Invest In.
Top 10 Holdings of Caligan Partners
In this piece, we will take a look at the Top 10 holdings of Caligan Partners. Founded in 2017, Caligan Partners is one of the most significant specialty hedge funds.
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q2 2024 Earnings Call Transcript
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q2 2024 Earnings Call Transcript May 6, 2024 Enanta Pharmaceuticals, Inc.
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q1 2024 Earnings Call Transcript
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q1 2024 Earnings Call Transcript February 7, 2024 Enanta Pharmaceuticals, Inc.
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q4 2023 Earnings Call Transcript
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q4 2023 Earnings Call Transcript November 20, 2023 Enanta Pharmaceuticals, Inc. beats earnings expectations.
Top 5 Stock Picks of Farallon Capital
In this article, we discuss the top 5 stock picks of Farallon Capital.
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q3 2023 Earnings Call Transcript
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q3 2023 Earnings Call Transcript August 7, 2023 Enanta Pharmaceuticals, Inc. misses on earnings expectations.
Hedge Fund Resource Center